Study to Develop a Breath Analyser to Detect Chronic Kidney Disease
Overview
Measure trimethylamine oxide in the breath.
Full Title of Study: “Pilot Study to Develop a Breath Analyser to Detect Chronic Kidney Disease”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 30, 2023
Detailed Description
Organic compounds such as trimethylamine oxide (TMAO) accumulate in the blood of patients with kidney disease, and volatile compounds such as TMAO can be detected in the breath. The investigators wish to develop a breath analyser to measure volatile compounds, such as TMAO in the breath in patients with kidney disease.
Interventions
- Diagnostic Test: breath
- measurement of volatile compounds, such as TMAO in exhaled breath and blood
Arms, Groups and Cohorts
- patients on dialysis
- patients with kidney disease treated by dialysis
- patients with chronic kidney disease
- patients with chronic kidney disease not treated by dialysis
Clinical Trial Outcome Measures
Primary Measures
- measurement of breath TMAO
- Time Frame: 3 years
- measurement of breath TMAO by breath analyser
Participating in This Clinical Trial
Inclusion Criteria
- patients with kidney disease under the care of Royal Free Hospital Exclusion Criteria:
- patients unable to provide informed consent – patients unable to exhale into breath analyser
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University College, London
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- andrew davenport, md, Principal Investigator, UCL, London
- Overall Contact(s)
- andrew davenport, md, 442077940500, andrewdavenport@nhs.net
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.